CHERRY DEOLASO: Open Payments
NPI 1174030712 · CARLSBAD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,200 in 52 payments from 13 companies in 2025. Trend: 2023 $823 · 2024 $769 · 2025 $1,200
Food & beverage: $1,019Education: $181
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 23 | $350 |
| AstraZeneca Pharmaceuticals LP | 3 | $197 |
| SANOFI-AVENTIS U.S. LLC | 2 | $164 |
| Insmed, Inc. | 10 | $143 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $108 |
| Amgen Inc. | 2 | $56 |
| GENZYME CORPORATION | 2 | $48 |
| Viatris Specialty LLC | 1 | $30 |
| Verona Pharma, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
Products named: DUPIXENT, TRELEGY ELLIPTA, NUCALA, AIRSUPRA, Arikayce, TEZSPIRE, JASCAYD, OFEV.
Industry payments across CA — which companies pay providers there.
